Answers are grounded in this paper and cite their sources.
Patients with CD59 deficiency have progressive neurologic dysfunction and episodes of hemolytic anemia. Eculizumab, a complement inhibitor, was administered to reverse hemolytic anemia in a patient. After the anemia improved, neurologic improvement was also noted.
No takes yet. Share an insight, caveat, or question.
Höchsmann et al. (2014) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: